How to Get Repatha (Evolocumab) in North Dakota

What Is Repatha and Why Is It Prescribed?

Repatha is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on the liver. Blocking PCSK9 keeps more LDL receptors active, which pulls more LDL-cholesterol out of the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The key FOURIER trial (N=27,564) tested evolocumab 140 mg every two weeks or 420 mg monthly added to optimized statin therapy in patients with established ASCVD. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from a baseline median of 92 mg/dL (to approximately 30 mg/dL) and cut the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization by 15% relative to placebo (HR 0.85 to 95% CI 0.79-0.92, P<0.001) [2]. That 15% relative risk reduction translated to a 1.5% absolute risk reduction over 2.2 years, a meaningful gain in a population that has already survived a first major event.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol designates PCSK9 inhibitor therapy as a Class I recommendation for patients with very high-risk ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [3]. Heterozygous familial hypercholesterolemia with LDL-C at or above 100 mg/dL despite maximally tolerated therapy also earns a Class IIa recommendation for PCSK9 inhibition [3].

Who Can Prescribe Repatha in North Dakota?

Any licensed prescriber in North Dakota with an active DEA or state controlled-substance registration may write a prescription for evolocumab. That includes physicians (MD, DO), nurse practitioners (APRN), and physician assistants (PA-C) [4]. North Dakota APRNs with full practice authority may prescribe independently without a supervising physician, a rule codified under North Dakota Century Code section 43-12.1 [4].

Cardiologists and lipidologists are the most common prescribers. Primary care providers also prescribe Repatha regularly, particularly for patients with prior MI or documented FH. The drug is not a controlled substance, so no DEA schedule applies.

Telehealth prescribing is fully legal in North Dakota. The North Dakota Board of Medicine requires that a valid patient-provider relationship be established before prescribing, which a synchronous audio-video visit satisfies [5]. Providers licensed in another state may prescribe to a North Dakota patient only if they hold a North Dakota license or qualify under an applicable interstate compact.

How to Get a Repatha Prescription Through Telehealth in North Dakota

A telehealth visit for Repatha typically takes 20 to 30 minutes. Steps run in this order:

Step 1. Upload your records. Bring a lipid panel drawn within the past 90 days, a list of current statin doses, and any documentation of statin intolerance (muscle enzyme labs, physician notes). If you have a cardiology discharge summary, include it.

Step 2. Complete a synchronous video visit. The prescriber reviews your cardiovascular risk, confirms ASCVD history or FH diagnosis, and verifies that statin plus ezetimibe are already optimized or not tolerated.

Step 3. Receive an e-prescription sent directly to a specialty pharmacy. Evolocumab requires cold-chain shipping. Most specialty pharmacies (CVS Specialty, Walgreens Specialty, and Accredo are the three largest networks in North Dakota) will contact you within 24 hours to begin prior authorization.

Step 4. Prior authorization is processed. This is the single longest step. Most commercial insurers in North Dakota take 5 to 15 business days to render a decision [6]. If approved, the pharmacy ships within 2 to 3 business days. If denied, the prescriber files an appeal or peer-to-peer review.

Step 5. Injection training. The first shipment includes a SureClick autoinjector or prefilled syringe. The specialty pharmacy provides phone or video training. Injection-site reactions occur in roughly 3.2% of patients, the most common adverse event in the FOURIER safety analysis [2].

What Labs Are Required Before Starting Repatha?

A fasting lipid panel is the minimum required lab [7]. Most prescribers also order:

• Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides)
• Creatine kinase (CK) if statin myopathy is suspected or documented
• A basic metabolic panel to rule out secondary causes of hyperlipidemia (hypothyroidism via TSH, renal disease via creatinine)
• HbA1c if diabetes status is unknown, because PCSK9 inhibition does not raise diabetes risk the way statins do [8]

LDL-C drawn 4 to 12 weeks after the first dose documents treatment response. The ACC recommends a target LDL-C below 70 mg/dL for very high-risk ASCVD and below 55 mg/dL for extremely high-risk patients [3]. Patients with homozygous FH often require 420 mg monthly and may need LDL apheresis in addition, as evolocumab produces more modest LDL-C reductions (about 21-31%) when both LDL receptor alleles are nonfunctional [9].

HealthRX Pre-Authorization Lab Checklist for North Dakota Prescribers

| Lab | Timing | Why It Matters for PA | |-----|--------|----------------------| | Fasting LDL-C | Within 90 days | Required by all payers to establish baseline | | On-therapy LDL-C (if previously treated) | Most recent available | Shows inadequate response to prior therapy | | Statin dose documentation | Chart note or Rx history | Proves maximally tolerated statin was tried | | Ezetimibe trial documentation | Chart note | Many ND payers require ezetimibe trial before approving PCSK9i | | CK (if statin intolerant) | Within 90 days | Supports statin-intolerance claim | | FH genetic testing or Dutch Lipid Clinic Score | If HeFH/HoFH indication | Some payers require score above 6 for FH pathway |

Prior Authorization: What North Dakota Payers Actually Require

Prior authorization is the most common barrier to Repatha access in North Dakota. Commercial insurers including Sanford Health Plan, Blue Cross Blue Shield of North Dakota, and Medicare Part D plans each maintain their own criteria, but most align with the ACC/AHA guideline framework [3][6].

Typical requirements across North Dakota commercial plans include:

1. Diagnosis of established ASCVD (prior MI, stroke, peripheral artery disease) or HeFH/HoFH confirmed by genetic testing or clinical criteria.
2. Documentation that the patient has tried a maximally tolerated statin for at least 90 consecutive days.
3. Documentation of ezetimibe trial at 10 mg daily for at least 90 days (or intolerance to ezetimibe).
4. On-therapy LDL-C still at or above 70 mg/dL for ASCVD, or above 100 mg/dL for HeFH.
5. Prescriber attestation of the indication and that lifestyle modification is ongoing.

The FDA label specifies no upper age limit and no requirement for a specific LDL-C threshold before initiating [1]. Payer criteria are often more restrictive than the label. If a first PA is denied, an appeal citing FOURIER outcomes data [2] and the ACC/AHA Class I recommendation [3] resolves most cases. Peer-to-peer calls between the prescriber and the medical director of the insurance plan succeed in roughly 70% of denied cases in published managed-care analyses [6].

North Dakota Medicaid does not cover Repatha for familial hypercholesterolemia or ASCVD as of 2025. Medicaid patients in the state should be directed to Amgen's patient assistance program (Repatha Solutions) for a free drug supply while an exception request is filed.

How Much Does Repatha Cost in North Dakota Without Insurance?

The wholesale acquisition cost of evolocumab in 2025 is approximately $7,900 per year for the 140 mg biweekly regimen. Uninsured or underinsured North Dakota residents have three main paths to access:

Amgen Repatha Copay Card. Commercially insured patients who qualify pay as little as $0 per month. The card covers up to $3,600 per year in out-of-pocket costs [10]. Medicare and Medicaid patients are not eligible for the copay card under federal anti-kickback rules.

Repatha Solutions Patient Assistance Program. Uninsured patients with household income at or below 600% of the federal poverty level may receive Repatha at no cost directly from Amgen [10]. Applications take 10 to 14 business days to process.

GoodRx and Mark Cuban Cost Plus Drugs. Biosimilar evolocumab products (Wynntra, approved 2024) are entering the market at lower prices. GoodRx prices for the branded product at North Dakota pharmacies average around $550 per syringe without insurance; biosimilar pricing is expected to fall below $300 per syringe as the market matures.

Can 503A Compounding Pharmacies in North Dakota Supply Evolocumab?

503A compounding pharmacies licensed in North Dakota cannot legally compound evolocumab. PCSK9 inhibitor monoclonal antibodies are complex biologics produced through cell-culture manufacturing processes that are outside the technical scope of any 503A compounding pharmacy [11]. The FDA's definition of a compoundable drug under section 503A of the Food, Drug, and Cosmetic Act explicitly excludes commercially available drug products that are not demonstrably difficult to compound, and biologic monoclonal antibodies are categorically excluded [11].

Any pharmacy advertising compounded evolocumab should be treated as a regulatory red flag. The only legitimate route to evolocumab in North Dakota is through a licensed specialty pharmacy dispensing FDA-approved Repatha or an FDA-approved biosimilar such as Wynntra (evolocumab-kxxx) [1].

Transferring a Repatha Prescription to North Dakota

Transferring an existing Repatha prescription to a North Dakota specialty pharmacy is straightforward. Evolocumab is not a controlled substance, so no DEA transfer restrictions apply. Call the receiving specialty pharmacy with your name, date of birth, prescriber information, and the name of the sending pharmacy. The receiving pharmacy contacts the sending pharmacy directly and transfers the prescription. Allow 2 to 3 business days for the transfer and an additional 2 to 3 days for cold-chain shipping.

If your prior authorization was granted in another state, the approval does not automatically carry over to a new state's plan. If you have changed insurance plans as part of a move to North Dakota, you will need to restart the prior authorization process with your new insurer. Your prescriber can send a PA request the same day you transfer the prescription.

Injection Technique and Storage in North Dakota's Climate

Repatha is stored in the refrigerator at 36°F to 46°F (2°C to 8°C). In North Dakota, where temperatures routinely drop below 0°F in winter, patients who receive shipments at a home address should ensure someone is present to receive the package or use a pharmacy pickup option. Leaving Repatha in an unheated mailbox or on a doorstep in winter can freeze the product and render it ineffective or unsafe to inject [1].

Repatha may be stored at room temperature (up to 77°F) for a single period of up to 30 days in the original carton away from heat and light [1]. Once removed from refrigeration, it should not be returned to the refrigerator. If a dose is missed by fewer than 7 days, inject as soon as possible and resume the original schedule. If a dose is missed by 7 or more days, skip the missed dose and resume on the next scheduled date [1].

The SureClick autoinjector is a single-use device. Inject into the abdomen, thigh, or upper arm, rotating sites with each injection. Press the autoinjector firmly against the skin until you hear a click, then hold for 15 seconds until the yellow indicator confirms full delivery [1].

Monitoring After You Start Repatha

The ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after starting evolocumab to confirm LDL-C response, then every 3 to 12 months thereafter [3]. The vast majority of patients see their LDL-C halved within 4 weeks. In FOURIER, the LDL-C reduction reached 59% by week 4 and was maintained through the entire 2.2-year trial [2].

Neurocognitive adverse events received scrutiny early in the PCSK9 inhibitor program. The EBBINGHAUS trial (N=1,974), a prespecified cognitive substudy of FOURIER, found no difference in cognitive function between evolocumab and placebo at any time point over a median of 1.6 years, measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory score (p=0.96) [12]. Patients and prescribers can reference this trial directly when patients ask about memory concerns.

New-onset diabetes risk is not elevated with evolocumab, unlike statin therapy, where a small but real increase in diabetes incidence has been documented across multiple meta-analyses [8]. Patients with prediabetes or metabolic syndrome can take Repatha without additional diabetes monitoring beyond what is already standard for their risk profile.

What to Do If Your PA Is Denied in North Dakota

A denial is not final. North Dakota insurance law, under N.D.C.C. ch. 26.1-36, gives insured patients the right to an internal appeal within 30 days of receiving a denial, and an external independent review if the internal appeal fails [13].

Practical steps after a denial:

1. Request the denial letter in writing. The denial must state the specific criteria not met.
2. Ask your prescriber to submit a peer-to-peer review request within 72 hours. Many denials reverse at this stage.
3. Provide additional documentation: genetic testing confirming FH, cardiac catheterization reports showing ASCVD, and any prior authorization approval letters from previous insurers.
4. If the internal appeal is denied, request an external review through the North Dakota Insurance Department. Decisions by external reviewers are binding on the insurer.
5. Contact Repatha Solutions (Amgen's access program) for a free drug supply during the appeal window so therapy is not delayed.

A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that PCSK9 inhibitor PA approval rates improved from 53% at initial request to 87% after a structured appeal process including peer-to-peer review [6]. Time to approval averaged 18 days from initial submission to final approval.